Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO306 oncolytic vaccinia virus in advanced refractory solid tumors
NCT07128914Phase 1Recruiting
- Sponsor
- GeneSail Biotech
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GO306 in breast cancer, bladder urothelial carcinoma (UC), colorectal cancer (CRC) and 4 more, sponsored by GeneSail Biotech. Primary endpoints: Adverse Events at 6 months, Serious Adverse Events at 6 months and 3 more. Started Jul 2025; status: recruiting.
02
Drugs
GO306
03
Conditions
breast cancerbladder urothelial carcinoma (UC)colorectal cancer (CRC)renal cell carcinoma (RCC)ovarian epithelial cancer
Beyond the preview
Go deeper on NCT07128914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128914.